WOCKPHARMA2024-07-012024-09-30 WOCKPHARMA2024-07-012024-09-30 WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2024-09-30 WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2024-04-01 2025-03-31 2024-11-13 2024-11-08 INR Crores Half yearly 11:25:00 13:20:00 2024-11-13 2024-11-13 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2024-07-01 2024-09-30 Unaudited Consolidated 8090000000.00 90000000.00 8180000000.00 1820000000.00 1500000000.00 -350000000.00 1610000000.00 730000000.00 550000000.00 2410000000.00 8270000000.00 -90000000.00 0.00 -90000000.00 30000000.00 40000000.00 70000000.00 0.00 -160000000.00 0.00 0.00 0.00 0.00 -160000000.00 890000000.00 730000000.00 -220000000.00 60000000.00 590000000.00 140000000.00 770000000.00 5 -1.47 -1.47 0.00 0.00 -1.47 -1.47 0.00 0.00 0.00 Notes To Consolidated Results:- 1.The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 13, 2024. The results have been subjected to Limited review by the Statutory Auditors of the Company. 2.The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 3.Key Financials on Standalone basisParticulars 3 months 3months 3 months 6 months 6 months year ended ended 30.09.24 ended 30.06.24 ended 30.09.23 ended 30.09.24 ended 30.09.23 31.03.24 Unaudited unaudited unaudited unaudited unaudited audited Total Income 381 379 266 759 523 1,195 Loss before (36) 6 (107) (30) (222) (422) tax Loss after (36) 6 (107) (30) (222) (422) tax Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 4.Further to the approval of the Board of Directors and Shareholders at their meetings , the Company has, on November 11, 2024, alloted 9,049,773 Equity Shares of Rs. 5/- each to successful Qualified Institutional Buyers at the issue price of Rs.1,105/- per share, aggregating to approximately Rs. 1,000 crore. 5.During the quarter ended September 30, 2024 , the Company has allotted 8,610 ( Year to date: 8,610) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 6.The Group is exclusively into Pharmaceutical business Segment. 7.For List of Subsidiaries as on September 30, 2024 please refer Annexure. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 15480000000.00 390000000.00 15870000000.00 3320000000.00 3030000000.00 -250000000.00 3210000000.00 1460000000.00 1090000000.00 4160000000.00 16020000000.00 -150000000.00 0.00 -150000000.00 50000000.00 120000000.00 170000000.00 0.00 -320000000.00 0.00 0.00 0.00 0.00 -320000000.00 850000000.00 530000000.00 -360000000.00 40000000.00 400000000.00 130000000.00 770000000.00 5 -2.42 -2.42 0.00 0.00 -2.42 -2.42 0.00 0.00 0.00 Exchange fluctuation loss, net 200000000.00 Other Expense 2210000000.00 Exchange fluctuation loss, net 210000000.00 Other Expense 3950000000.00 3180000000.00 18060000000.00 4810000000.00 0.00 9910000000.00 500000000.00 14070000000.00 0.00 0.00 0.00 0.00 0.00 660000000.00 660000000.00 5880000000.00 1910000000.00 55800000000.00 6570000000.00 480000000.00 6950000000.00 1430000000.00 320000000.00 0.00 350000000.00 9530000000.00 0.00 2940000000.00 19040000000.00 1040000000.00 0.00 75880000000.00 770000000.00 33180000000.00 33950000000.00 37130000000.00 12190000000.00 0.00 1230000000.00 13420000000.00 300000000.00 530000000.00 0.00 700000000.00 14950000000.00 9350000000.00 6770000000.00 5640000000.00 21760000000.00 1450000000.00 490000000.00 100000000.00 0.00 23800000000.00 0.00 0.00 38750000000.00 75880000000.00 Notes to Assets Liabilities: 1. Property, Plant and Equipment of Rs.1806 crore includes Right of use assets amounting to Rs. 474 crore. 2. Other non-current assets of Rs. 191 crore includes Non-current tax assets (net) amounting to Rs. 79 crore. 3. Other non-current financial liabilities consists of Lease liabilities amounting to Rs.123 crore. 4. Other current financial liabilities of Rs. 564 crore include Lease liabilities amounting to Rs.66 crore. 5. Non-current assets classified as held for sale represents Assets classified as held for sale. Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2024 as attached to the Outcome of Board Meeting. Notes to Cash Flow Statements 1. Proceeds from issuance of shares includes transaction cost relating to Right Issue of Rs. 2 Crore. 2. Proceeds from borrowing of Rs. 322 crore includes proceeds from term loan Rs. 299, short term borrowings Rs. net - 24 crore and loan from Related Parties long term of Rs. 47 crore. 3.Repayment of borrowing Rs.344 crore includes repayment of long term borrowings Rs.327 crore, repayment of loan taken from Related Parties-long term Rs. 4 crore and short term Rs.13 crore. 4.Other inflows (outflows) of cash consists of Finance cost paid Rs. 88 crore. 5.Aggregated/segregated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2024 as attached to the Outcome of Board Meeting 1460000000.00 40000000.00 -600000000.00 0.00 0.00 -530000000.00 0.00 0.00 0.00 0.00 0.00 -950000000.00 0.00 1090000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 60000000.00 0.00 0.00 0.00 0.00 0.00 -340000000.00 0.00 110000000.00 -40000000.00 0.00 0.00 0.00 -360000000.00 0.00 320000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3170000000.00 480000000.00 70000000.00 3640000000.00 0.00 1550000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 40000000.00 0.00 -80000000.00 0.00 -2470000000.00 0.00 0.00 -20000000.00 0.00 0.00 0.00 0.00 0.00 3220000000.00 3440000000.00 0.00 350000000.00 0.00 880000000.00 0.00 0.00 -1470000000.00 -3620000000.00 0.00 -3620000000.00 5050000000.00 1430000000.00 tems that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset) -2600000.00 Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge) 0.00 Rounding Off 2600000.00 tems that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset) -10000000.00 Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge) 0.00 Rounding Off 0.00 0.00 -10000000.00 0.00 0.00 Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations) 890000000.00 Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations) 860000000.00 890000000.00 860000000.00 0.00 0.00